Solid Tumor Testing Market Size

Solid Tumor Testing Market Size

The global solid tumor testing market size was valued at around USD 20.5 billion in 2023 and is estimated to grow at 7.6% CAGR from 2024 to 2032. Rising cancer incidences and increasing awareness and demand are driving the growth of the market.

The growing prevalence of cancer significantly impacts the demand for accurate and timely diagnostic solutions, leading to the expansion of the market. As more individuals are diagnosed with various types of solid tumors, healthcare providers are compelled to enhance their testing capabilities to ensure effective treatment and management.
 

Several factors contribute to the rising cancer rates, including unhealthy lifestyle choices such as poor diet, physical inactivity, tobacco use, and excessive alcohol consumption, all of which have been linked to an increased risk of cancer. For example, according to the Centers for Disease Control and Prevention (CDC), nearly 1.78 million new cases of invasive cancer occurred in the U.S. in 2021, with an incidence rate of 439 per 100,000 people.
 

Additionally, growing awareness and demand for solid tumor testing are significantly driving market growth by encouraging early detection and personalized treatment options. As patients and healthcare providers become more informed about the benefits of genomic testing and biomarker profiling, there is an increasing push for advanced diagnostic solutions that can lead to better treatment outcomes. This heightened awareness is also fostering investments in research and development, further propelling innovations in testing technologies.
 

Solid tumor testing refers to molecular diagnostic testing that analyzes a solid mass of cancerous tissue to identify genetic mutations, biomarkers, or other molecular characteristics. This testing helps guide treatment decisions, such as selecting targeted therapies or immunotherapies, and assessing the likelihood of cancer recurrence.